大家 基嗣

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 70%
3. Urinary Bladder Neoplasms 53%
4. Neoplasms 40%
5. Nephroureterectomy 34%
6. Carcinoma 34%
7. Castration 33%
8. Recurrence 29%
9. Prostate-Specific Antigen 25%
10. Prostatectomy 21%
11. Neoplasm Metastasis 21%
12. Prostate 20%
13. Kidney 19%
14. Therapeutics 19%
15. Survival 18%
16. cabazitaxel 16%
17. Nephrectomy 14%
18. Adrenalectomy 13%
19. Japan 13%
20. Docetaxel 13%
21. Axitinib 12%
22. Androgens 11%
23. Drug Therapy 11%
24. Brachytherapy 11%
25. Sunitinib 10%
26. Sorafenib 10%
27. Cystectomy 10%
28. Nivolumab 9%
29. Urinary Bladder 9%
30. Bacillus 9%
31. Cisplatin 9%
32. Multivariate Analysis 9%
33. Survival Rate 9%
34. Tomography 8%
35. Angiomyolipoma 8%
36. Neoplasm Grading 8%
37. Safety 8%
38. Biopsy 7%
39. Progression-Free Survival 7%
40. Biomarkers 7%
41. Platinum 7%
42. Urinary Tract 7%
43. Renal Dialysis 6%
44. Aldosterone 6%
45. Interleukin-2 6%
46. dehydroxymethylepoxyquinomicin 6%
47. C-Reactive Protein 6%
48. Molecular Targeted Therapy 6%
49. Kidney Neoplasms 6%
50. Magnetic Resonance Imaging 6%